Crossmark

Tumor residue in patients with stage II–IVA nasopharyngeal carcinoma who received intensity-modulated radiation therapy: development and validation of a prediction nomogram integrating postradiotherapy plasma Epstein–Barr virus deoxyribonucleic acid, clinical stage, and radiotherapy dose

Crossref DOI link: https://doi.org/10.1186/s12885-023-10827-0

Published Online: 2023-05-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Huang, Ying-Ying

Zhou, Jia-Yu

Zhan, Ze-Jiang

Ke, Liang-Ru

Xia, Wei-Xiong

Cao, Xun

Cai, Zhuo-Chen

Deng, Ying

Chen, Xi

Zhang, Lu-Lu

Huang, Hao-Yang

Guo, Xiang

Lv, Xing
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (81872375, 82172863)

Basic and Applied Basic Research Foundation of Guangdong Province (2021A1515010118)
License Information

Text and Data Mining valid from 2023-05-06

Version of Record valid from 2023-05-06
More Information

Article History

Received: 11 November 2022

Accepted: 7 April 2023

First Online: 6 May 2023

Declarations

:

: This retrospective study was approved by the Institutional Review Board of Sun Yat‐Sen University Cancer Center (B2021-215–01). All of the participants provided written informed consent before treatment. All methods were carried out in accordance with Declaration of Helsinki.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below